LungTraXPlatform

Search documents
Pulmonx to Report First Quarter 2025 Financial Results on April 30, 2025
Globenewswire· 2025-04-16 20:05
Core Viewpoint - Pulmonx Corporation is set to release its financial results for Q1 2025 on April 30, 2025, and will host a conference call to discuss these results [1]. Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [3]. - The company’s key products include the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report, which are designed for patients with severe emphysema/COPD [3]. - The Zephyr Valve has received FDA pre-market approval as a "breakthrough device" and is commercially available in over 25 countries, recognized as a standard treatment option for improving the quality of life in patients with severe emphysema [3].